Insulin governs developmental processes and exerts influence on ovarian physiology as well as pathology [49, 55]
Death from a cardiovascular event, nonfatal myocardial infarction (heart attack), or nonfatal stroke occurred during the trial in 6.5% of patients who were treated with semaglutide versus 8.0% of patients who received placebo a 20% reduction in relative risk by semaglutide
While gastrointestinal symptoms dominate the side effect profile of GLP-1 receptor agonists, dermatological concerns deserve attention because they affect quality of life and treatment continuation
When diarrhea typically starts GI symptoms, including diarrhea, typically emerge within the first days to weeks after starting semaglutide or increasing your dose
As a dual GIP/GLP-1 receptor agonist, it targets two hormonal pathways instead of one
Your doctor will monitor appropriate clinical markers (heart function, blood tests, etc.) to gauge effectiveness